Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
复制标题
DOI：
10.1158/1940-6207.capr-14-0058
复制
发表时间：
2014-09
期刊：
影响因子：
--
通讯作者：
Thompson IM
中科院分区：
文献类型：
--
作者：
Albanes D;Till C;Klein EA;Goodman PJ;Mondul AM;Weinstein SJ;Taylor PR;Parnes HL;Gaziano JM;Song X;Fleshner NE;Brown PH;Meyskens FL Jr;Thompson IM
硒和维生素E癌症预防试验（SELECT）显示，补充高剂量α-生育酚的男性前列腺癌发病率较高。因此，我们研究了补充前血浆α-生育酚或γ-生育酚是否与总体或高级别前列腺癌相关。分层病例队列样本包括2009年6月诊断的1,746例前列腺癌病例和3,211例男性亚队列，来自35,533例男性的SELECT试验。在2001-2004年入组时采集血浆，中位随访时间为5.5年（范围：0 - 7.9年）。通过风险比（HR）估计前列腺癌的发病率与血浆α-生育酚、γ-生育酚以及补充α-生育酚或硒代蛋氨酸的关系。血浆γ-生育酚与前列腺癌无关。α-生育酚浓度较高的男性的风险似乎与浓度较低的男性相似[第五个五分位数（Q5）与第一个五分位数（Q1）的总体HR，1.21（95%置信区间（CI），0.88-1.66，P趋势=0.24;在试验安慰剂组中，Q5 HR，0.85，95% CI，0.44-1.62，P趋势=0.66]。我们发现，在接受硒代蛋氨酸补充剂试验的男性中，血浆α-生育酚呈强阳性相关[Q5 HR，2.04，95% CI，1.29-3.22; P趋势=0.005]。血浆α-生育酚与前列腺癌的阳性相关性似乎也仅限于高级别疾病（Gleason分级7- 10，总体Q5 HR，1.59，95% CI，1.13-2.24，P趋势=0.001;在接受硒代蛋氨酸的男性中，HR，2.12，95% CI，1.32-3.40; P趋势=0.0002）。我们的研究结果表明，较高的血浆α-生育酚浓度可能与硒代蛋氨酸补充剂相互作用，增加高级别前列腺癌的风险，这表明α-生育酚和硒本身或硒代蛋氨酸之间的生物相互作用。
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed higher prostate cancer incidence in men supplemented with high-dose α-tocopherol. We therefore examined whether pre-supplementation plasma α-tocopherol or γ-tocopherol was associated with overall or high-grade prostate cancer. A stratified case-cohort sample that included 1,746 incident prostate cancer cases diagnosed through June, 2009 and a subcohort of 3,211 men was derived from the SELECT trial of 35,533 men. Plasma was collected at entry in 2001–2004, and median follow-up was 5.5 years (range, 0 – 7.9 years). Incidence of prostate cancer as a function of plasma α-tocopherol, γ-tocopherol, and supplementation with α-tocopherol or selenomethionine was estimated by the hazard ratio (HR). Plasma γ-tocopherol was not associated with prostate cancer. Men with higher α-tocopherol concentrations appeared to have risk similar to that of men with lower concentrations [overall HR for fifth (Q5) vs. first quintile (Q1), 1.21 (95% confidence interval (CI), 0.88–1.66, P-trend=0.24; in the trial placebo arm, Q5 HR, 0.85, 95% CI, 0.44–1.62, P-trend=0.66]. We found a strong positive plasma α-tocopherol association among men receiving the trial selenomethionine supplement [Q5 HR, 2.04, 95% CI, 1.29–3.22; P-trend=0.005]. A positive plasma α-tocopherol-prostate cancer association also appeared limited to high-grade disease (Gleason grade 7––10, overall Q5 HR, 1.59, 95% CI, 1.13–2.24, P-trend=0.001; among men receiving selenomethionine, HR, 2.12, 95% CI, 1.32–3.40; P-trend=0.0002). Our findings indicate that higher plasma α-tocopherol concentrations may interact with selenomethionine supplements to increase high-grade prostate cancer risk, suggesting a biological interaction between α-tocopherol and selenium itself or selenomethionine.